Novel compounds
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N″-substituted-N′-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
72 Citations
28 Claims
-
1. A compound of the formula:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
2. The compound according to claim 1 which is Formula (I), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
3. The compound according to claim 1 which is Formula (Ia), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
4. The compound according to claim 1 wherein R1 is optionally substituted one or more times independently at each occurrence by substituents selected from halogen, C1-4 alkyl, halo-substituted-C1-4 alkyl, hydroxy, cyano, nitro, (CR10R20)vNR4R14, (CR10R20)vC(Z)NR4R14, (CR10R20)vC(Z)OR8, (CR10R20)vCORc, (CR10R20)vC(O)H, SR5, S(O)R5, S(O)2R5, (CR10R20)vOR8, ZC(Z)R11, N(R10′
- )C(Z)R11, or N(R10′
)S(O)2R7; and
whereinR4 and R14 are each independently selected at each occurrence, by hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, heterocyclic, or heterocyclic C1-4 alkyl;
or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9;
R5 is independently selected, at each occurrence by hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR4R14, excluding the moieties SR5 being SNR4R14, S(O)2R5 being SO2H and S(O)R5 being SOH;
R7 is independently selected from C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;
R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl;
R10 and R20 are independently selected at each occurrence, from hydrogen or C1-4alkyl;
R10′
is independently selected at each occurrence, from hydrogen or C1-4alkyl;
R11 is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)tOR7, (CR10R20)tS(O)mR7, (CR10R20)t N(R10′
)S(O)2R7, or (CR10R20)vNR4R14; and
wherein the aryl, arylalkyl, heteroaryl, heteroaryl C1-4 alkyl, heterocyclyl, and heterocyclyl C1-4 alkyl moieties may be optionally substituted;
Rc is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)vOR7, (CR10R20)vS(O)mR7, (CR10R20)vN(R10′
)S(O)2R7, or (CR10R20)vNR4R14; and
wherein the alkyl, cycloalkyl, cycloalkenyl, aryl, aryl C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, heterocyclic and heterocyclic C1-4 alkyl moieties may be optionally substituted;
m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2;
t is an integer having a value of 1 to 3;
v is 0 or an integer having a value of 1 or 2; and
Z is independently selected from oxygen or sulfur.
- )C(Z)R11, or N(R10′
-
5. The compound according to claim 4 wherein R1 is an optionally substituted phenyl or naphthyl.
-
6. The compound according to claim 5 wherein the phenyl is substituted one or more times independently by halogen, C1-4 alkyl, (CR10R20)vOR8, (CR10R20)vNR4R14 or halo-substituted-C1-4 alkyl.
-
7. The compound according to claim 6 wherein the substituent is halogen, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
8. The compound according to claim 7 wherein the substituents are independently selected from fluorine, chlorine, methyl, or CF3.
-
9. The compound according to claim 5 wherein the aryl ring is a phenyl ring, and the ring is mono-substituted in the 2, 4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2,4,6-position.
-
10. The compound according to claim 9 wherein R1 is phenyl, 2-methyl-4-fluorophenyl, 2-methylphenyl, 2-chlorophenyl, 2-fluorophenyl, or 2-methyl-3-fluorophenyl.
-
11. The compound according to claim 1 wherein the R3 moiety is optionally substituted one or more times independently with C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7cycloalkenyl, C5-7cycloalkenylC1-10 alkyl, halogen, cyano, nitro, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
- )S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10′
)C(═
N(R10′
))NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)NR4R14, or (CR10R20)nN(R10′
)C(Z)OR7; and
whereinR4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, heterocyclic, or heterocyclic C1-4 alkyl;
or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9;
R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted independently one or more times;
R7 is C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted independently one or more times;
R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl, wherein the optional substituents are independently substituted;
R10 and R20 are independently selected from hydrogen or C1-4alkyl;
R10′
is independently selected from hydrogen or C1-4alkyl;
m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2;
n is 0 or an integer having a value of 1 to 10; and
Z is independently selected at each occurrence from oxygen or sulfur.
- )S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
-
12. The compound according to claim 11 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
13. The compound according to claim 12 wherein the optional substituents are independently selected at each occurrence from halogen, C1-10 alkyl, halo-substituted C1-10 alkyl, (CR10R20)nOR6, or (CR10R20)nNR4R14.
-
14. The compound according to claim 13 wherein the optional substituents are halogen, methyl, hydroxy, alkoxy, amino, or CF3.
-
15. The compound according to claim 11 wherein R3 is phenyl, 4-trifluoromethyl-phenyl, 2-fluorophenyl, 2,6-difluoro-phenyl, 2,4-difluoro-phenyl, 2-chlorophenyl, 2-methylphenyl, or 2,6-dimethylphenyl.
-
16. The compound according to claim 1 wherein R2 and R2′
- are independently hydrogen or C1-10 alkyl,
-
17. The compound according to claim 1 wherein Rg is an optionally substituted C1-10 alkyl.
-
18. The compound according to claim 1 which is:
-
N-cyano-N′
-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)guanidine;
N-cyano-N′
-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)-N″
-methylguanidine;
N-cyano-N′
-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)-N″
-ethylguanidine;
N-Cyano-N′
-(2-{[4-(2,4-difluorophenyl)-8-(2-fluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)guanidine;
N-Cyano-N′
-(2-{[8-(2,6-difluorophenyl)-4-(2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)guanidine;
N-Cyano-N′
-(2-{[8-(2,6-difluorophenyl)-4-(4-fluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)guanidine;
N-cyano-N′
-(2-{[4-(2,4-difluorophenyl)-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}ethyl)guanidine; and
a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
-
19. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
-
20. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound according to claim 1.
-
21. The method according to claim 20 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter'"'"'s syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and brain and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, thrombosis, glomerularnephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, atheroschlerosis, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, neurodegenrative disease, muscle degeneration, atheroschlerosis, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, influenza induced pneumonia, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.
-
22. A method of treating the inflammatory component of the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human in need thereof which method comprises administering to said human an effective amount of a compound according to claim 1.
-
23. The method according to claim 22 wherein the respiratory viral infection exacerbates asthma, exacerbates chronic bronchitis, exacerbates chronic obstructive pulmonary disease, exacerbates otitis media, exacerbates sinusitis, or wherein the respiratory viral infection is associated with a secondary bacterial infection, otitis media, sinusitis, or pneumonia.
-
24. A method of treating, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
25. A method of treating, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, or chronic obstructive pulmonary disease (COPD) in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
26. A method of treating atherosclerosis, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
27. A method of treating inflammation in a mammal in need thereof comprising administering to said mammal an effective amount of a compound according to claim 1.
-
28. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative, according to claim 1, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
-
2. The compound according to claim 1 which is Formula (I), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGlaxo Group Limited (Glaxosmithkline Holdings Ltd.)
-
Original AssigneeGlaxo Group Limited (Glaxosmithkline Holdings Ltd.)
-
InventorsBoehm, Jeffrey C., Taggart, John J.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/264.110
-
CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 11/00 Drugs for disorders of the ...A61P 11/02 Nasal agents, e.g. deconges...A61P 11/04 for throat disordersA61P 11/06 AntiasthmaticsA61P 11/08 BronchodilatorsA61P 11/16 Central respiratory analepticsA61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 17/04 AntipruriticsA61P 17/06 AntipsoriaticsA61P 17/16 Emollients or protectives, ...A61P 19/02 for joint disorders, e.g. a...A61P 19/06 Antigout agents, e.g. antih...A61P 19/08 for bone diseases, e.g. rac...A61P 19/10 for osteoporosisA61P 21/00 Drugs for disorders of the ...A61P 25/00 Drugs for disorders of the ...A61P 27/02 Ophthalmic agentsA61P 29/00 Non-central analgesic, anti...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/12 : AntiviralsA61P 33/06 : AntimalarialsA61P 35/00 : Antineoplastic agentsA61P 35/04 : specific for metastasisA61P 37/00 : Drugs for immunological or ...A61P 37/02 : ImmunomodulatorsA61P 43/00 : Drugs for specific purposes...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 9/00 : Drugs for disorders of the ...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/08 : Vasodilators for multiple i...A61P 9/10 : for treating ischaemic or a...C07D 471/04 : Ortho-condensed systems